24 Zoledronic acid (ZOL) as add-on therapy in patients with tumour residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36)
G. von Minckwitz, M.D. Zahm, H. Eidtmann, H. Tesch, A. du Bois, K. Schwedler, J. Hilfrich, C. Jackisch, K. Mehta, B. GerberVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70055-0
File:
PDF, 47 KB
english, 2010